Aldeyra Therapeutics Submits IND Filing to FDA for Clinical Testing of NS2 in Patients with Sjögren-Larsson Syndrome
January 5, 2015Aldeyra Therapeutics submitted an Investigational New Drug (IND) application to the FDA on December 30th to conduct Phase 2 clinical testing of NS2 for the treatment of the rare disease Sjögren-Larsson Syndrome (SLS).
More »
ACHILLION SHOWS POTENTIAL FOR “BEST-IN-DISEASE” HCV REGIMEN - 100% SVR4 FOLLOWING A DUAL 6-WEEK ACH-3102-BASED REGIMEN AND SEPARATELY A 4.8 LOG10 REDUCTION WITH ACH-3422
December 22, 2014ACHILLION SHOWS POTENTIAL FOR “BEST-IN-DISEASE” HCV REGIMEN - 100% SVR4 FOLLOWING A DUAL 6-WEEK ACH-3102-BASED REGIMEN AND SEPARATELY A 4.8 LOG10 REDUCTION WITH ACH-3422
More »
Celator® Pharmaceuticals Receives European Patent Allowance on Nanoparticle Delivery Technology
December 18, 2014Celator Pharmaceuticals’ proprietary system, called the “Improved Taxane Delivery System”, is allowed by the European Patent Office. This should help establish the applicability of their CombiPlex platform in developing cancer therapies.
More »